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The purpose of this study was to examine the effects of ZD6126, a novel vascular-targeting agent, on tumour growth and
angiogenesis in an orthotopic model of gastric cancer. TMK-1 human gastric adenocarcinoma cells were injected into the gastric wall
of nude mice. After the tumours were established (day 14), therapy was initiated. Mice (n¼11–12/group) received (a) vehicle,
(b) ZD6126 at 100mgkgday
 1 i.p. one time per week or (c) ZD6126 at 100mgkgday
 1 i.p. five times per week. Tumour mass,
volume and the presence or absence of peritoneal carcinomatosis were determined at sacrifice on day 38. Tumours from each group
were stained for markers of blood vessels, proliferation and apoptosis. To further define the time frame of the vascular-targeting
effects of chronic therapy with ZD6126, TMK-1 cells were again injected into the gastric wall of mice in a second experiment. On day
14, a single i.p. injection of ZD6126 100mgkg
 1mouse
 1 or vehicle was delivered. Groups of three mice each were killed and the
tumours harvested at days 1, 3 and 5 post-ZD6126 injection. Tumours were processed and stained for endothelial and tumour cell
apoptosis and proliferation. No overt toxicity was observed with ZD6126 therapy. ZD6126 led to a marked inhibition of tumour
growth (82% decrease vs control (Po0.001)). ZD6126 also led to a significant decrease in the incidence of peritoneal carcinomatosis
(10 out of 12 controls, vs one out of 12 ZD6126) (Po0.01). Histological analysis of tumours revealed large regions of central necrosis
in the treated group, as well as a dramatic increase in tumour cell apoptosis (7.4-fold increase (Po0.001)), consistent with the
vascular-targeting activity of ZD6126. Mice treated with ZD6126 demonstrated a 59% decrease in PCNA-positive cells (Po 0.02),
indicating reduced tumour cell proliferation. In addition, tumours treated with ZD6126 exhibited a 40% decrease in microvessel
density (Po0.05). Results from mice treated with a single injection of ZD6126 demonstrated the acute effects this agent has on the
tumour vasculature. The ratio of endothelial cell apoptosis to endothelial cell proliferation was increased within 24h of a single
injection. In conclusion, ZD6126 significantly inhibited tumour growth and metastasis in an orthotopic model of human gastric
adenocarcinoma, without detectable problematic adverse effects. These data suggest that ZD6126 may be worthy of investigation in
the treatment of primary gastric adenocarcinoma.
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The 5-year survival rate for patients with gastric cancer in the
United States is only 5–15% (Karpeh et al, 2001). The mortality
associated with gastric cancer has remained relatively stable over
the past 20 years, suggesting that new therapies to combat this
problem are urgently needed (Karpeh et al, 2001). Recent studies
have shown that targeting the tumour vasculature may be of
therapeutic benefit in gastric cancer (Mori et al, 2000; Yoshikawa
et al, 2000; Jung et al, 2002; Kamiyama et al, 2002).
The generation and maintenance of a functional vasculature is
necessary for tumours to increase in size beyond 1–2mm
(Folkman, 1992). Anti-angiogenic agents target biological pro-
cesses involved in the generation of new blood vessels, for
example, by blocking the receptor-ligand systems important for
the angiogenic response (Bruns et al, 2000; Jung et al, 2002).
However, by the time the cancer is diagnosed, most tumours
already have an intact, functional vascular network (Folkman,
1992). Significantly, tumour vasculature seems to be fundamentally
different from normal vasculature (Denekamp, 1990). For example,
tumour endothelium is characterised by tortuous, leaky vessels
with chaotic blood flow (Fukumura et al, 1997) and a significant
proportion of immature, proliferating endothelial cells, which is in
contrast to the ordered vessels and quiescent endothelial cells
found in normal tissues (Skinner et al, 1995; Brown and Giaccia,
1998). Targeting the phenotypic differences between tumour
vasculature and normal vasculature is particularly attractive
because it has the potential to be effective against established
tumours, which are often considered to be resistant to standard
chemotherapeutic approaches.
In contrast to anti-angiogenic therapies, vascular targeting
therapies aim to selectively and irreversibly disrupt tumour blood
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sflow, inducing prolonged ischaemia and subsequent secondary
necrotic tumour cell death (Reviewed in (Chaplin and Hill, 2002).
A wide range of potentially effective vascular-targeting approaches
has been described, each exploiting distinctive features of the
tumour vasculature (Denekamp, 1990; Bloemendal et al, 1999;
Thorpe et al, 2003). Vascular-targeting activity is a common
feature of tubulin-binding microtubule destabilising agents such as
colchicines and vinca alkaloids. Although these agents have
significant vascular-targeting activity in animal tumour models
(Chaplin et al, 1996) this is only seen at or around their maximum
tolerated dose (MTD). More than half a century ago, colchicine,
one of the oldest known tubulin-binding agents, was found to
cause extensive central necrosis and hemorrhage of tumours when
administered to cancer patients, presumably through vascular-
targeting activity (Seed et al, 1940). However significant toxicity
prevented its further clinical development as an anti-cancer agent.
Therefore, newer agents that more selectively disrupt tumour
vasculature with a wider therapeutic margin over normal tissue
effects have been sought for clinical evaluation. In particular, two
compounds currently in phase II clinical development (combre-
tastatin A-4 phosphate and ZD6126) have demonstrated selective
effects on tumour vasculature in animal models at doses
significantly below their MTD (Dark et al, 1997; Davis et al,
2002). Although the molecular mechanisms underlying the
vascular-targeting activity of these agents is not well understood,
a range of in vitro endothelial cell responses (eg cytoskeletal
reorganisation, cell shape change) and in vivo vascular responses
(eg vascular collapse, increased permeability, decreased perfusion)
have been described that could play a significant role in their anti-
tumour effects (Griggs et al, 2001; Blakey et al, 2002; Davis et al,
2002).
ZD6126, is a novel vascular-targeting agent that was developed
for its ability to bind tubulin and induce vascular damage in
tumours (Davis et al, 2002). It has a wide therapeutic index in
mouse tumour models producing selective antivascular effects in
tumours at doses ranging from 1/8th to 1/16th of the MTD in mice
(Davis et al, 2000; Blakey et al, 2002; Siemann and Rojiani, 2002).
ZD6126 has significant antitumour effects in a wide range of
histologically distinct subcutaneous tumour xenografts in nude
mice (Blakey et al, 2002). However, the efficacy of ZD6126 has not
been examined at orthotopic sites where the endothelia are
phenotypically distinct and tumour growth is likely to be more
physiologically relevant to human disease (Craig et al, 1998; Chi
et al, 2003).
The aim of this study was to determine the efficacy of single-
agent ZD6126 therapy on tumour growth and vasculature in an
orthotopic model of gastric cancer.
MATERIALS AND METHODS
Cell culture
TMK-1, a poorly differentiated human gastric adenocarcinoma cell
line, was a generous gift of Dr Eiichi Tahara (Hiroshima
University, Hiroshima, Japan), and was cultured and maintained
in Dulbecco’s modified Eagle medium supplemented with 10%
fetal bovine serum, as described previously (Jung et al, 2002).
Formulation of ZD6126
ZD6126, a phosphate prodrug of N-acetylcolchinol, was provided
by AstraZeneca (Macclesfield, England). ZD6126 was dissolved in
5% sodium carbonate and diluted to the final volume with
phosphate-buffered saline (PBS), as previously described (Blakey
et al, 2002). Solutions were sterilised by filtration through a 0.22-
mm filter and stored at 41C.
Animal studies
Male athymic mice, 8-week old (obtained from the National Cancer
Institute Animal Production Area, Frederick, MD, USA), were
acclimated for 1 week and caged in groups of five. All animal
studies were conducted under the guidelines approved by the
Animal Care and Use Committee of The University of Texas MD
Anderson Cancer Center, and met all of the standards required by
the UKCCCR guidelines for the welfare of animals in experimental
neoplasia, as published (Workman et al, 1998).
Mice were anaesthetised by i.p. injection of sodium phenobar-
bital (Nembutal, 50mgkg
 1) and, under sterile conditions,
subjected to an upper midline laparotomy. TMK-1 cells (10
6)i n
Hank’s balanced salt solution were injected into the wall of the
mid-stomach. After 14 days, when tumours were approximately 1–
2mm in diameter, mice were randomly assigned to one of three
groups: (a) daily-dose control (PBSþ5% sodium carbonate, pH
7.0, n¼12); (b) weekly-dose ZD6126 (100mgkg
 1, 1 dayweek
 1);
and (c) daily-dose ZD6126 (100mgkg
 1, 5 daysweek
 1, n¼11)
(Figure 1). The weekly dose group received four injections of
ZD6126 on days 14, 21, 28 and 35, and received the last injection 3
days prior to sacrifice. The daily dose group received 18 injections
(days 14–18, 21–25, 28–32, 35–37) and received the last injection
24h prior to sacrifice. Body weight at randomisation was similar
among groups and animals in all groups gained weight at a similar
rate throughout the experiment. Since this tumour model can
result in animals rapidly becoming moribund from bowel
obstruction, mice were very closely monitored for signs of loss
of clinical condition associated with morbidity. In this experiment,
all mice were euthanised by CO2 asphyxiation on day 38 when 25%
of the control mice showed clinical signs (lack of activity and
increase tumour burden on palpation), indicating that they would
be expected shortly to become moribund. Body weights were
measured, tumours were excised, tumour weight and diameters
were subsequently determined and the presence or absence of
peritoneal carcinomatosis was noted. Tumour volumes were
calculated by the equation width
2 length 0.5. Tumour tissue
was harvested and placed in either 10% buffered formalin for
paraffin fixation or optimal cutting temperature (OCT) compound
(Miles Inc., Elkhart, IN, USA) and frozen in liquid nitrogen for
subsequent immunohistochemical analysis.
In a separate experiment to clarify the timing of the antivascular
effect of ZD6126, mice bearing established orthotopic tumours
were injected with a single dose of ZD6126 (100mgkg
 1)o r
control solution (PBSþ5% sodium carbonate) 14 days after
tumour-cell implantation. These mice were injected i.p. with 1mg/
0.2ml of 5-bromo-20-deoxyuridine (BrdU) (Sigma, St Louis, MO,
USA) dissolved in PBS 1h before euthanasia to determine the
fraction of proliferating cells. Three mice per group were
euthanised at days 1, 3, or 5 after a single injection of ZD6126,
and the tumour tissues were harvested as above.
Immunostaining of microvessels, proliferative and
apoptotic cells
Tissue sections were sectioned and stained for H&E, CD31
(vessels), TUNEL (apoptotic cells), BrdU (proliferative cells) and
PCNA (proliferative cells), as previously described (Reinmuth et al,
2002; Stoeltzing et al, 2003). All tumour tissues were counter-
stained either with Gill’s 3 haematoxylin (Sigma; immunochisto-
chemical analysis), or incubated with 300mg/ml of Hoechst stain
for 1–2min (Sigma, immunofluorescent analysis). The antibodies
used were as follows: rat anti-mouse CD31 (Pharmingen, San
Diego, CA, USA), mouse anti-BrdU (Becton Dickinson, Franklin
Lakes, NJ, USA), mouse anti-human PCNA PC-10 (DAKO,
Carpinteria, CA, USA), DeadEnd Fluorometric TUNEL system
(Promega, Madison, WI, USA), rat anti-mouse IgG2a (Serotec,
Raleigh, NC, USA), Texas Red goat anti-rat secondary antibody
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s(Jackson Research Laboratories, West Grove, CA, USA) and goat
anti-mouse IgG Alexa Fluor 488 (Molecular Probes, Eugene, OR,
USA).
Analysis of immunostained tissue sections
Sections were examined using a Zeiss photomicroscope (Carl Zeiss
Inc., Thornwood, NY, USA) equipped with a 3-chip charge-
coupled device colour camera (DXC-960 MD; Sony Corp., Tokyo,
Japan). The images were analysed using Optimas image analysis
software (version 5.2; Bothell, WA, USA). Positive cells were
counted using Scion software, based on the NIH Image program
for Macintosh (Scion Corporation, Frederick, MD, USA). Quanti-
fication of positive cells was expressed as the average of the
number of cells in 0.05-mm
2 high-power fields at  200. Five fields
from one 8–10mm section per tumour specimen were chosen
randomly and 3–5 specimens per group underwent analysis. Each
field contained more than 2000 cells. Areas of obvious necrosis (as
determined by either the haematoxylin or Hoechst counterstain)
were avoided. The ratio of endothelial cell apoptosis to endothelial
cell proliferation was determined by counting the number of
CD31-positive/TUNEL-positive cells divided by the number of
CD31-positive/BrdU-positive cells per high-power field.
Statistical analysis
Statistical differences among groups were examined using the two-
tailed Student’s t-test, the w
2 test, or, for analysis of nonparametric
data, the Mann–Whitney U-test with InStat Statistical Software
(GraphPad Software, San Diego, CA, USA). The results of the in
vivo experiments were tested for outliers using Grubb’s test
(www.graphpad.com). A P-value of less than 0.05 was considered
statistically significant.
RESULTS
Effect of ZD6126 on growth of primary gastric tumours
No difference was discerned in the body weight or grooming habits
of the treatment groups (multiple-dose ZD6126, single-dose
ZD6126, or control). The effects of ZD6126 on the growth of
TMK-1 cells implanted into the stomach walls of nude mice are
shown in Table 1. Tumour volume was reduced in both the weekly-
dose group (45% decrease, Po 0.05) and the daily-dose group
(82% decrease, Po0.002) (Figure 2, Table 1). Tumour mass was
less in the group given daily ZD6126 than in the control mice
(Po0.05), but weekly ZD6126 did not significantly reduce tumour
mass relative to that in the control group (P¼0.26).
Effect of ZD6126 on incidence of peritoneal carcinomatosis
TMK-1 cells are known to induce peritoneal carcinomatosis in a
similar mouse model (Minagawa et al, 2001). In our study, daily
ZD6126 therapy led to a reduction in the incidence of peritoneal
deposits: 83% of the control mice developed gross peritoneal
carcinomatosis, and this was reduced to less than 10% of mice
treated with daily ZD6126 (Po0.01) (Table 1). Weekly ZD6126 did
not significantly affect the development of carcinomatosis (50%
incidence, P¼0.08 vs controls).
Decreased microvessel density in ZD6126-treated animals
Immunohistochemical staining for CD31 to determine the micro-
vessel density revealed no difference between the control mice and
those given weekly ZD6126. However, microvessel density was
reduced by 40% in mice treated daily with ZD6126 relative to that
in the control group (Po0.05) (Table 2, Figure 3).
Tumour cell proliferation and cell death in ZD6126-treated
animals
The proliferative and apoptotic rates of the tumour cells in each of
the three groups are shown in Table 2 and Figure 3. Significantly
fewer PCNA-positive cells were found in tumours in the ZD6126-
treated groups (53% fewer in the weekly group (Po0.01) and 58%
fewer in the daily group (Po0.05)), concomitant with significant
increases in TUNEL-positive cells in both groups (5.3-fold increase
Table 1 Treatment of gastric cancer with ZD6126
ZD6126 (100mgkg
 1)
Control Weekly Daily
Body mass (g)7s.e.m. 30.970.8 31.371.0 29.270.7
Tumour volume (mm
3)7s.e.m. 4407154 241739
b 79725
a
Tumour mass (g)7s.e.m. 0.570.1 0.470.1 0.270.1
b
Incidence of carcinomatosis 10/12 (83.3%) 6/12 (50%) 1/11 (9.1%)
c
TMK-1 was injected into the gastric wall on day 0. Therapy with ZD6126, either once
a week (weekly) or 5  per week (daily), was initiated on day 14. Mice were killed on
day 38.
aPo0.002 by Student’s t-test.
bPo0.05 by Student’s t-test.
cPo0.01 by w
2
analysis.
Gastric
injection of
TMK-1 cells
0
ZD6126 or
control
  i.p.
Euthanasia and
tumour harvest
Days
ZD6126 : 100 mgkg−1day−1 (i.p.)
14 38
ZD6126 weekly
(n=12)
ZD6126 daily
(n=11)
Control
(n=12)
Solvent:   PBS (i.p.)
Figure 1 Experimental design of ZD6126 therapy for gastric cancer
growing in an orthotopic site. TMK-1 human gastric cancer cells (10
6) were
injected into the gastric walls of nude mice. Mice were randomised to one
of three groups: control, ZD6126 1 dayweek
 1, or ZD6126 5 days
week
 1. Treatment with ZD6126 (100mgkg
 1) or control began on day
14 by i.p. injection. On day 38, all mice were euthanised.
Control
ZD6126
weekly
ZD6126
daily
Figure 2 Effects of ZD6126 on gastric tumour growth. TMK-1 cells
(10
6) were injected into the stomach walls of nude mice, and therapy was
begun on day 14. Photographs show that daily ZD6126 administration was
more effective in inhibiting tumour growth than daily administration or
control.
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sin the weekly group (Po0.007) and 7.4-fold increase in the daily
group (Po0.001)).
Endothelial cell apoptosis and proliferation
Tumours harvested from mice treated with ZD6126 either weekly
or daily for 38 days were stained for markers of endothelial-cell
apoptosis (CD31/TUNEL), to determine whether the decrease in
microvessel density was associated with increased endothelial cell
apoptosis. However, at that relatively late time point, no apoptotic
endothelial cells were detected (data not shown). Therefore, to
examine the acute effects of ZD6126 on the tumour microvascu-
lature, mice bearing established tumours were injected with a
single dose of ZD6126 (100mg/kg) on day 14, and tumours were
harvested 1, 3, or 5 days after the injection. As shown in Table 3, at
day 1 post-ZD6126 injection, there was a significant decrease in the
number of proliferating cells, as determined by the percent of
BrdU-positive cells (61% decrease (Po0.004)). There was also a
concomitant increase in cell death at day 1, which was sustained
through to day 5 (15-fold increase at day 1 (Po0.05) and nine-fold
increase at day 5 (Po0.05)). Importantly, there was also a
significant decrease in endothelial cell proliferation by day 1
post-ZD6126 injection (56% decrease in CD31þ/BrdUþ cells
(Po0.05)). However, since the process of angiogenesis is
determined by a balance between proliferating and apoptotic
endothelial cells, the ratio of these two parameters was determined.
As shown in Table 3, ZD6126 led to a significant increase in the
ratio of endothelial cell apoptosis to proliferation (57%: Po0.01).
This increase was apparent as early as 24h post-ZD6126 injection,
and continued through day 5.
DISCUSSION
Our findings in this study demonstrate the efficacy of selectively
targeting the tumour vasculature with the novel antivascular agent
ZD6126 in an orthotopic model of human gastric cancer. Previous
studies have described ZD6126, both as a single agent and in
combination with radiation and chemotherapy, in various models
in which tumour cells are implanted in subcutaneous tissues
(Blakey et al, 2002; Siemann et al, 2002; Siemann & Rojiani, 2002).
Here we focus on the efficacy of single-agent ZD6126 therapy,
administered in two dose schedules, in an orthotopic model of
gastric cancer.
Daily dosing with ZD6126 (100mgkg
 1, 5 days per week) caused
a significant inhibition of tumour growth. Once-weekly dosing, in
contrast, reduced the tumour volume, but did not significantly
reduce tumour mass. This difference may be due to the variability
of excising and weighing the tumour, as it is difficult to ensure
complete removal of the tumour, without the accompanying
uninvolved stomach wall. This is reflected by the proportionately
greater variability in the tumour mass measurement, especially as
the tumour volume is reduced. Previous studies in subcutaneous
xenograft tumour models have shown that a single bolus dose of
ZD6126 produces widespread central tumour necrosis with a rim
of viable tumour cells surviving treatment, which can quickly
repopulate the tumour mass, resulting in limited tumour growth
delay (Blakey et al, 2002). These tumour cells are not killed
following drug treatment, presumably because they gain oxygen
and nutrients from blood vessels in the surrounding normal tissue,
which is unaffected by ZD6126 (Blakey et al, 2002). Therefore, in a
rapidly growing tumour model system, repeated dosing of ZD6126
is required to obtain significant tumour growth delays (Blakey et al,
2002; Davis et al, 2002). We observe greater antitumour effects
with the daily dosing schedule, which may reflect a greater
opportunity for regrowth of tumour between doses of ZD6126 in
the weekly schedule.
Examination of the tumour samples at the end of the experiment
(day 38), 24h after the last dose of ZD6126 was administered,
showed that both treatment schedules produced significant
antitumour effects in terms of increased tumour cell death
(TUNEL-positive staining), together with decreased tumour cell
proliferation (PCNA-positive staining). However, the TUNEL-
staining procedure can detect both apoptotic and necrotic cell
death (Grasl-Kraupp et al, 1995), and, therefore, it does not clearly
discriminate between these two modes of cell death. Despite that,
the increase in TUNEL-positive cells is more likely due to an
increase in apoptosis as areas of intense necrosis (as determined
either by H&E staining or the Hoechst counterstain) were avoided.
Additionally, many of the fields that were chosen had only diffuse
Table 2 Treatment of gastric cancer with ZD6126
ZD6126 (100mgkg
 1)
Control Weekly Daily
Microvessel density # of vessels/HPF 12.071.5 10.171.2 7.271.6
a
Proliferating cells # of cells/HPF 16.972.5 8.071.1
b 7.071.3
a
Apoptotic cells # of cells/HPF 2.070.4 10.873.7
b 15.073.0
c
TMK-1 was injected into the gastric wall on day 0. Therapy with ZD6126, either once
a week (weekly) or 5  per week (daily), was initiated on day 14. Mice were killed on
day 38. Tumours were harvested and tissue sections were stained with antibodies
against CD31 to determine the microvessel density, PCNA to determine the cycling
cells, or TUNEL to determine apoptotic cells. Measurements are the mean7the
standard error, as determined by counting the positive cells in each of five  200
high-powered fields (HPF) for at least five tumours from each treatment or control
group.
aPo0.05.
bPo0.01.
cPo0.001.
Figure 3 Immunohistochemical analysis of gastric tumours. Representa-
tive images of tumour sections stained with haematoxylin and eosin (row 1;
 200 magnification), stained immunohistochemically for CD31 (row 2;
 200) or for PCNA (row 3;  200), or stained for apoptosis by TUNEL
(row 4,  200). Weekly ZD6126 caused a significant decrease in the
number of PCNAþ proliferating cells and an increase in TUNEL-positive
apoptotic cells; daily ZD6126 decreased microvessel density (as shown by
staining with antibodies against CD31), decreased proliferating cells
(PCNA) and increased apoptotic cells (TUNEL).
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sTUNEL-positive cells surrounded by areas of viable tissues, again
indicative of apoptosis and not necrosis. Tumours isolated from
animals following weekly or daily dosing schedules of ZD6126
appeared to have a higher degree of morphological tumour
necrosis on H&E sections (data not shown). Taken together with
the increase in TUNEL staining in the tumours compared with the
controls, this would be consistent with a vascular-targeting
mechanism of action for ZD6126 in this anti-tumour study.
In these experiments, we did not observe increased endothelial
cell death in gastric tumours examined at the end of either the
daily or weekly ZD6126 treatment schedule. However, ZD6126
treatment has been shown to induce rapid occlusion of tumour
blood vessels (within 6h), probably as a result of drug-induced
effects on endothelial cell shape, leading to exposure of basement
membrane and rapid induction of endothelial cell apoptosis and
subsequent loss of vessel function (Blakey et al, 2002). Therefore,
detecting endothelial cells undergoing apoptosis after multiple
rounds of treatment may be very difficult, since the bulk of the
potentially ZD6126-sensitive endothelial cells throughout the
tumour would be affected at the earliest times of the treatment
regimen. At later times, endothelial cell proliferation and vessel
growth would be expected to be more localised around areas of the
tumour that are nourished from nontumour vessels (e.g. at the
tumour rim) which are unaffected by ZD6126 (Blakey et al, 2002).
To further investigate the dynamics of ZD6126 effects on
endothelial cell apoptosis and proliferation, we treated mice
bearing established tumours with a single injection of ZD6126,
and harvested the tumours 1, 3 and 5 days later. Immunohisto-
chemical analysis revealed that microvessel density tended to
decrease following ZD6126 injection, reaching statistical signifi-
cance on day 5. This corresponded with a decrease in proliferating
endothelial cells following ZD6126 treatment. Taken together,
these observations may indicate that TMK-1 tumour regrowth and
revascularisation are decoupled at early times after ZD6126
treatment, perhaps because angiogenesis is not rate limiting to
tumour growth in the early-stage gastric tumours. Examination of
H&E sections revealed that widespread necrosis was evident 1–3
days after ZD6126 treatment. Multiple areas of focal necrosis were
evident throughout the tumour mass, surrounded by regions of
viable tumour tissue. By day 5, the extent of histological tumour
necrosis was reduced, as demonstrated in Figure 4. This most
likely represents tumour regrowth, as has been described in
rapidly proliferating subcutaneous xenograft models (Blakey et al,
2002).
Previously, ZD6126 was shown to have significant antitumour
activity in a human lung pulmonary metastasis model in nude
mice (Goto et al, 2002). In this metastasis model, ZD6126
antitumour activity was associated with selective induction of
apoptosis in tumour endothelial cells 24h after ZD6126 treatment,
with associated destruction of the tumour vasculature. However,
despite the widespread tumour necrosis in the lung metastases,
repeated dosing was required to reduce disease burden, consistent
with what has been described for other rapidly growing tumours
(Blakey et al, 2002; Davis et al, 2002). In the present study, ZD6126
treatment reduced the incidence of peritoneal carcinomatosis,
which may be a consequence of reducing the growth of the primary
gastric tumour rather than a direct effect on the metastatic
deposits in the peritoneum. In contrast to the study by Goto et al
(2002), we did not see a significant increase on endothelial cell
apoptosis within the tumour even at 24h after ZD6126 treatment.
The reason for the difference between the two studies is not
Table 3 Treatment of gastric cancer with ZD6126: time course
ZD6126 (100mgkg
 1)
Control Day 1 Day 3 Day 5
Tumour weight (g) 0.670.3 0.370.06 0.270.01 0.370.02
Tumour volume (mm
3) 250.1775.7 242.6731.0 167.8747.3 134.2734.6
Proliferating cells # of cells/HPF 112.377.3 43.7714.7
a 78.4714.6
b 33.0710.0
a
Apoptotic cells # of cells/HPF 0.870.3 12.076.6
b 16.277.9
c 7.273.3
b
Microvessel density # of vessels/HPF 32.972.7 29.372.4 25.772.9 22.872.6
a
Proliferating EC # of cells/HPF 2.570.4 1.170.3
b 1.170.18
c 1.370.3
b
Apoptotic EC # of cells/HPF 0.670.1 0.770.3 1.270.3 0.670.1
Ratio of apoptotic to proliferating ECs (% control) 0.3 0.6
c (57%) 1.1
c (67%) 0.8
b (68%)
TMK-1 tumours growing in the gastric wall were harvested at 1 day, 3 days and 5 days post-ZD6126 injection. Tissue sections were stained with antibodies against CD31, BrdU
and TUNEL to determine MVD, endothelial cell proliferation and endothelial cell apoptosis. Measurements are the mean7the standard error, as determined by counting the
positive cells in each of five  100 high-powered fields (HPF) for three tumours from each treatment or control group. EC¼endothelial cell.
aPo0.004.
bPo0.05.
cPo0.01.
Figure 4 Immunohistochemical analysis of gastric tumours after a single
dose of ZD6126. Representative images of tumour sections stained with
haematoxylin and eosin (column 1;  40 magnification), stained for
endothelial cell proliferation by immunofluorescence for CD31/BrdU
(column 2;  100) and stained for endothelial cell apoptosis by
immunofluorescence against CD31/TUNEL (column 4,  100). A single
dose of ZD6126 caused a significant decrease in the number of dividing
endothelial cells (as determined by colocalisation) and an increase in
endothelial cells undergoing apoptosis, such that microvessel density was
decreased by day 5.
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scertain, but it is possible that the apoptotic response of tumour
endothelial cells to vascular-targeting agents may depend on the
tumour microenvironment within each disease site. However,
despite the differences in induction of tumour endothelial cell
apoptosis, ZD6126 produced significant antitumour effects in both
disease models.
As reported by others (Blakey et al, 2002; Goto et al, 2002), the
effects of ZD6126 appear to be very selective for tumour
vasculature. We did not observe any increase in cell death within
the histologically normal tissues surrounding the tumour, either in
epithelial or endothelial cells (data not shown).
The activity of combretastatin A-4 phosphate has been reported
in several physiologically relevant mouse models, including
orthotopic models of mouse (MAC 15) or human (SW620)
colorectal cancer (Grosios et al, 1999), models of human colon
cancer (DLD-1 and HT29) metastasis to the liver (Holwell et al,
2002) and orthotopic models of human NSCLC (KNS-62, Colo-699)
(Boehle et al, 2001). In the first of these studies, a single dose of
combretastatin A-4 phosphate (100mg/kg) induced extensive
haemorrhagic necrosis, with a rim of viable tumour at the
periphery of the primary colorectal tumour 24h after drug
treatment. This effect was also observed in vascular metastatic
deposits in the kidney, lymph nodes and abdominal wall, but no
effect was observed in avascular deposits in the lung (Grosios et al,
1999), supporting the hypothesis that the tumour necrosis induced
by the drug is secondary to vascular effects in the orthotopic
setting. In the follow-up study, a single dose of combretastatin A-4
phosphate (150mg/kg) also induced haemorrhagic necrosis in the
colorectal tumours within the liver 24h after drug treatment
(Holwell et al, 2002). The extent of necrosis induction was
significantly lower when SW620 was grown in the liver rather than
as a subcutaneous tumour, indicating that the tumour micro-
environment can affect the response of a tumour to vascular-
targeting agents. In the final study of two human NSCLC
xenografts, a daily regimen of combretastatin A-4 phosphate
(50mgkg
 1day
 1 for 21 days) significantly inhibited tumour
growth in both the subcutaneous and orthotopic settings (Boehle
et al, 2001).
The present study has shown that the vascular-targeting agent
ZD6126 was effective in reducing the growth and peritoneal spread
of human gastric cancer cells implanted orthotopically into the
stomach walls of nude mice. Furthermore, the antitumour activity
was improved with daily dosing compared with weekly dosing.
Further studies are needed to more completely define the
mechanism of action of this agent and to determine whether
additional antitumour effects can be seen in this model in
combination with clinically relevant chemotherapy, radiation
therapy, or antiangiogenic agents. However, the present preclinical
results provide support for investigating the potential activity of
ZD6126 in gastric cancer in the clinic.
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